Newsroom

Press Releases

Saniona Icon blue
May 25, 2022
  Q1 2022 ( Q1 2021 ) Revenue was SEK 6.6 M (3.4 M) Operating loss was SEK -133.2 M (-94.1 M) Net loss was SEK -133.4 M (-83.4 M) Loss per share was SEK -2.14 (-1.34) Diluted loss per share was SEK -2.14 (-1.34) Business highlights in Q1 2022 Saniona initiated the Multiple Ascending Dose (MAD)
May 20, 2022
PRESS RELEASE May 20 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that the Mexican regulatory authority Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) has published on Twitter that its technical
April 30, 2022
PRESS RELEASE April 30 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that the English version of the Annual Report for 202 1  is now available on the company’s website,   www.saniona.com .
April 27, 2022
PRESS RELEASE April 2 7 , 202 2 Saniona (OMX: SANION), a clinical - stage biopharmaceutical company focused on rare diseases, today announced that the Board of Directors of Saniona AB has resolved to change the date of the Annual Report for 2021 from April 29, 202 2 to April 30, 202 2 .
April 25, 2022
PRESS RELEASE April 2 5 , 202 2 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the annual shareholders’
Displaying 1 - 10 of 16